Takeda Submits Azilsartan NDA In Japan
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical submitted a new drug application for azilsartan March 22 with Japan's Ministry of Health, Labor and Welfare. The company views TAK-536 as a potential blockbuster drug to follow Blopress (candesartan).